MorphoSys AG
NASDAQ:MOR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
MorphoSys AG
NASDAQ:MOR
|
DE |
|
F
|
Fresenius SE & Co KGaA
XMUN:FRE
|
DE |
Intrinsic Value
The intrinsic value of MorphoSys AG (MOR) under the Base Case is 9.41 USD per share.
Compared with the current market price of 18.96 USD, the stock appears
Overvalued by 50% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What MorphoSys Does
MorphoSys AG emerged from the vibrant biotechnology landscape of Munich, Germany, in 1992. It was founded on the innovative idea of harnessing antibodies as a means to combat diseases. With a precision-driven approach to drug development, MorphoSys primarily concentrates on creating and bringing to market therapeutic agents for cancer and inflammatory disorders. Taking center stage is their proprietary technology platform that enables the discovery of monoclonal antibodies, pivotal in the fight against these daunting ailments.
- Headquarters
- Germany DE
- Employees
- 648
- IPO date
- Mar 9, 1999
Revenue & Expenses Breakdown
MorphoSys AG
Earnings Waterfall
MorphoSys AG
The intrinsic value for MorphoSys AG (MOR) under the Base Case is 9.41 USD.
Compared with the current market price of 18.96 USD, the stock appears Overvalued by 50% .
